MY198587A - Pharmaceutical compositions comprising a dextromethorphan compound and quinidine for the treatment of agitation in dementia - Google Patents
Pharmaceutical compositions comprising a dextromethorphan compound and quinidine for the treatment of agitation in dementiaInfo
- Publication number
- MY198587A MY198587A MYPI2017000321A MYPI2017000321A MY198587A MY 198587 A MY198587 A MY 198587A MY PI2017000321 A MYPI2017000321 A MY PI2017000321A MY PI2017000321 A MYPI2017000321 A MY PI2017000321A MY 198587 A MY198587 A MY 198587A
- Authority
- MY
- Malaysia
- Prior art keywords
- dementia
- quinidine
- agitation
- treatment
- pharmaceutical compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/49—Cinchonan derivatives, e.g. quinine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/22—Bridged ring systems
- C07D221/28—Morphinans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (18)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462050170P | 2014-09-14 | 2014-09-14 | |
| US201462061451P | 2014-10-08 | 2014-10-08 | |
| US201462063122P | 2014-10-13 | 2014-10-13 | |
| US201462063861P | 2014-10-14 | 2014-10-14 | |
| US201462068742P | 2014-10-26 | 2014-10-26 | |
| US201562111053P | 2015-02-02 | 2015-02-02 | |
| US201562111590P | 2015-02-03 | 2015-02-03 | |
| US201562128446P | 2015-03-04 | 2015-03-04 | |
| US201562162140P | 2015-05-15 | 2015-05-15 | |
| US201562165535P | 2015-05-22 | 2015-05-22 | |
| US201562169997P | 2015-06-02 | 2015-06-02 | |
| US201562180026P | 2015-06-15 | 2015-06-15 | |
| US201562193347P | 2015-07-16 | 2015-07-16 | |
| US201562205061P | 2015-08-14 | 2015-08-14 | |
| US201562216636P | 2015-09-10 | 2015-09-10 | |
| US201562217470P | 2015-09-11 | 2015-09-11 | |
| US201562217142P | 2015-09-11 | 2015-09-11 | |
| PCT/US2015/049934 WO2016040930A1 (en) | 2014-09-14 | 2015-09-14 | Pharmaceutical compositions comprising a dextromethorphan compound and quinidine for the treatment of agitation in dementia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY198587A true MY198587A (en) | 2023-09-06 |
Family
ID=55459653
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI2017000321A MY198587A (en) | 2014-09-14 | 2015-09-14 | Pharmaceutical compositions comprising a dextromethorphan compound and quinidine for the treatment of agitation in dementia |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US20190111047A1 (enExample) |
| EP (4) | EP3708168A3 (enExample) |
| JP (4) | JP2017531033A (enExample) |
| KR (1) | KR20170052684A (enExample) |
| CN (3) | CN110664801A (enExample) |
| AU (3) | AU2015314710A1 (enExample) |
| CA (1) | CA2960031A1 (enExample) |
| IL (2) | IL250786A0 (enExample) |
| MX (3) | MX2017003066A (enExample) |
| MY (1) | MY198587A (enExample) |
| PH (1) | PH12017500444A1 (enExample) |
| RU (1) | RU2017112747A (enExample) |
| SG (2) | SG11201701645WA (enExample) |
| TW (3) | TWI869633B (enExample) |
| WO (1) | WO2016040930A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2792662T3 (da) | 2007-05-01 | 2016-07-25 | Concert Pharmaceuticals Inc | Morphinanforbindelser |
| CA2994153A1 (en) * | 2015-07-30 | 2017-02-02 | Concert Pharmaceuticals, Inc. | Deuterated morphinan compounds for use in treating agitation |
| US20180243289A1 (en) * | 2015-07-30 | 2018-08-30 | Concert Pharmaceuticals, Inc. | Deuterated morphinan compounds for treating agitation |
| EP3825307B1 (en) * | 2016-07-04 | 2022-08-03 | Avanir Pharmaceuticals, Inc. | Methods for the synthesis of deuterated dextromethorphan |
| EP3618819A4 (en) * | 2017-05-04 | 2021-01-20 | Exciva GmbH | TARGETED DRUG RESCUE WITH NEW COMPOSITIONS, ASSOCIATIONS AND CORRESPONDING PROCESSES |
| US11478467B2 (en) | 2017-05-04 | 2022-10-25 | Sreenivasarao Vepachedu | Targeted drug rescue with novel compositions, combinations, and methods thereof |
| US12383526B2 (en) | 2018-05-18 | 2025-08-12 | Anavex Life Sciences Corp. | Optimized sigma-1 agonist method of responder selection and treatment |
| CR20210368A (es) * | 2019-01-07 | 2021-12-10 | Antecip Bioventures Ii Llc | Combinación de dextrometorfano y bupropión para el tratamiento de depresión |
| AU2020241611A1 (en) * | 2019-03-18 | 2021-11-04 | Avanir Pharmaceuticals, Inc. | Methods of treating negative symptoms of schizophrenia using deuterated dextromethorphan and quinidine |
| WO2021222145A1 (en) * | 2020-04-27 | 2021-11-04 | Avanir Pharmaceuticals Inc. | Methomethods of treating agitation associated with alzheimer's disease |
| CN115245515A (zh) * | 2021-04-27 | 2022-10-28 | 杭州剂泰医药科技有限责任公司 | 一种组合物的医药用途 |
| CN115322150B (zh) * | 2021-05-11 | 2024-05-28 | 深圳信立泰药业股份有限公司 | 氘代右美沙芬氢溴酸盐的固体及其制备方法和医药用途 |
| CN113209042A (zh) * | 2021-05-28 | 2021-08-06 | 珠海润都制药股份有限公司 | 一种氢溴酸右美沙芬硫酸奎尼丁胶囊及其制备方法 |
| KR20240110812A (ko) * | 2021-10-27 | 2024-07-16 | 아바니르 파마슈티컬스, 인코포레이티드 | 알츠하이머병과 관련된 불안을 치료하는 방법 |
| CN116459255A (zh) * | 2022-01-19 | 2023-07-21 | 深圳信立泰药业股份有限公司 | 氘代右美沙芬与安非他酮联合在制备ad激越的药物中的用途 |
| US11730706B1 (en) * | 2022-07-07 | 2023-08-22 | Antecip Bioventures Ii Llc | Treatment of depression in certain patient populations |
| CN117783322A (zh) * | 2022-12-16 | 2024-03-29 | 杭州剂泰医药科技有限责任公司 | 右美沙芬奎尼丁组合物的hplc分析方法 |
| KR20250120917A (ko) | 2024-02-02 | 2025-08-11 | 단국대학교 천안캠퍼스 산학협력단 | 덱스트로메토르판을 유효성분으로 포함하는 신경 질환 예방 또는 치료용 약학 조성물 |
| KR20250129211A (ko) | 2024-02-22 | 2025-08-29 | 단국대학교 천안캠퍼스 산학협력단 | 데가렐릭스를 유효성분으로 포함하는 신경 질환 예방 또는 치료용 약학적 조성물 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| US5206248A (en) | 1992-03-27 | 1993-04-27 | Smith Richard A | Method for reducing emotional lability |
| US5366980A (en) | 1991-06-17 | 1994-11-22 | Smith Richard A | Use of dextromethorphan and an oxidase inhibitor to treat dermatitis |
| US5350756A (en) | 1991-06-17 | 1994-09-27 | Smith Richard A | Use of a cytochrome oxidase inhibitor to increase the cough-suppressing activity of dextromorphan |
| US5166207A (en) | 1991-06-17 | 1992-11-24 | Neurotherapeutics, Inc. | Method for enhancing the systemic delivery of dextromethorphan for the treatment of neurological disorders |
| TW264473B (enExample) * | 1993-01-06 | 1995-12-01 | Hoffmann La Roche | |
| JP4097285B2 (ja) * | 1994-09-22 | 2008-06-11 | リチャード・アラン・スミス | 種々の頑固な疾患の治療のための医薬の製造に有用な組成物 |
| US5874443A (en) | 1995-10-19 | 1999-02-23 | Trega Biosciences, Inc. | Isoquinoline derivatives and isoquinoline combinatorial libraries |
| US5886210A (en) | 1996-08-22 | 1999-03-23 | Rohm And Haas Company | Method for preparing aromatic compounds |
| US5922683A (en) | 1997-05-29 | 1999-07-13 | Abbott Laboratories | Multicyclic erythromycin derivatives |
| EP2201945B1 (en) | 1997-11-21 | 2013-03-06 | Purdue Neuroscience Company | Use of substituted 2-aminoacetamides for treating or ameliorating anxiety |
| IL137974A0 (en) | 1998-03-26 | 2001-10-31 | Shionogi & Co | Indole derivatives having antiviral activity |
| US6509331B1 (en) | 1998-06-22 | 2003-01-21 | Elan Pharmaceuticals, Inc. | Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds |
| FR2784988B1 (fr) | 1998-10-23 | 2002-09-20 | Adir | Nouveaux composes dihydro et tetrahydroquinoleiniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| TWI326214B (en) * | 2002-07-17 | 2010-06-21 | Avanir Pharmaceuticals Inc | Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders |
| WO2007092329A2 (en) * | 2006-02-03 | 2007-08-16 | Avanir Pharmaceuticals | Pharmaceutical compositions for treating depression, anxiety and neurodegenerative disorders |
| US20070224128A1 (en) * | 2006-03-07 | 2007-09-27 | Donn Michael Dennis | Drug adherence monitoring system |
| WO2008097924A2 (en) * | 2007-02-05 | 2008-08-14 | Avanir Pharmaceuticals | Pharmaceutical compositions comprising dextromethorphan analogs for the treatment of neurological disorders |
| MX370608B (es) * | 2007-05-01 | 2019-12-18 | Concert Pharmaceuticals Inc | Compuestos de morfinano. |
| DK2792662T3 (da) * | 2007-05-01 | 2016-07-25 | Concert Pharmaceuticals Inc | Morphinanforbindelser |
| JP5730769B2 (ja) * | 2008-09-19 | 2015-06-10 | コンサート ファーマシューティカルズ インコーポレイテッド | モルヒナン化合物 |
| US20120083487A1 (en) * | 2008-10-30 | 2012-04-05 | Amanda Thomas | Combination of morphinan compounds and antidepressant for the treatment of pseudobulbar affect, neurolgical diseases, intractable and chronic pain and brain injury |
| MX2011005112A (es) * | 2008-11-14 | 2011-06-16 | Concert Pharmaceuticals Inc | Derivados de dioxopiperidinil-ftalimida sustituida. |
| EP3981403A1 (en) * | 2013-11-05 | 2022-04-13 | Antecip Bioventures II LLC | Compositions and methods comprising bupropion or related compounds and dextromethorphan |
-
2015
- 2015-09-14 TW TW110139834A patent/TWI869633B/zh active
- 2015-09-14 EP EP20159783.8A patent/EP3708168A3/en not_active Withdrawn
- 2015-09-14 CN CN201910903770.XA patent/CN110664801A/zh active Pending
- 2015-09-14 EP EP21178170.3A patent/EP3932907A3/en not_active Withdrawn
- 2015-09-14 CA CA2960031A patent/CA2960031A1/en active Pending
- 2015-09-14 WO PCT/US2015/049934 patent/WO2016040930A1/en not_active Ceased
- 2015-09-14 RU RU2017112747A patent/RU2017112747A/ru not_active Application Discontinuation
- 2015-09-14 TW TW109114123A patent/TW202106301A/zh unknown
- 2015-09-14 CN CN202311175974.9A patent/CN117427077A/zh active Pending
- 2015-09-14 MX MX2017003066A patent/MX2017003066A/es unknown
- 2015-09-14 AU AU2015314710A patent/AU2015314710A1/en not_active Abandoned
- 2015-09-14 US US15/510,498 patent/US20190111047A1/en not_active Abandoned
- 2015-09-14 EP EP22195837.4A patent/EP4166141A1/en not_active Withdrawn
- 2015-09-14 SG SG11201701645WA patent/SG11201701645WA/en unknown
- 2015-09-14 TW TW104130311A patent/TW201613591A/zh unknown
- 2015-09-14 KR KR1020177009991A patent/KR20170052684A/ko not_active Ceased
- 2015-09-14 CN CN201580049454.0A patent/CN107072990A/zh active Pending
- 2015-09-14 MY MYPI2017000321A patent/MY198587A/en unknown
- 2015-09-14 SG SG10201901242PA patent/SG10201901242PA/en unknown
- 2015-09-14 EP EP15840718.9A patent/EP3193872A4/en not_active Withdrawn
- 2015-09-14 JP JP2017533726A patent/JP2017531033A/ja active Pending
-
2017
- 2017-02-26 IL IL250786A patent/IL250786A0/en unknown
- 2017-03-08 MX MX2021010696A patent/MX2021010696A/es unknown
- 2017-03-08 MX MX2022008181A patent/MX2022008181A/es unknown
- 2017-03-09 PH PH12017500444A patent/PH12017500444A1/en unknown
-
2019
- 2019-10-08 US US16/596,236 patent/US20200289499A1/en not_active Abandoned
- 2019-11-06 JP JP2019201410A patent/JP2020019818A/ja not_active Withdrawn
-
2020
- 2020-05-18 IL IL274742A patent/IL274742A/en unknown
- 2020-12-15 AU AU2020289733A patent/AU2020289733A1/en not_active Abandoned
-
2021
- 2021-03-08 JP JP2021036318A patent/JP7360409B2/ja active Active
-
2022
- 2022-12-06 AU AU2022283671A patent/AU2022283671B2/en not_active Expired - Fee Related
-
2023
- 2023-04-24 US US18/305,589 patent/US20240082237A1/en not_active Abandoned
- 2023-06-12 JP JP2023096152A patent/JP2023105265A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12017500444A1 (en) | Pharmaceutical compositions comprising a dextromethorphan compound and quinidine for the treatment of agitation in dementia | |
| MX2021002321A (es) | Nuevos metodos. | |
| ZA202204929B (en) | Rimegepant for cgrp related disorders | |
| MX2021000071A (es) | Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer. | |
| MX393855B (es) | Terapia de combinación que comprende un inhibidor de raf y trametinib | |
| EA201590655A1 (ru) | Комбинация лахинимода и придопидина для лечения нейродегенеративных нарушений | |
| IN2015DN00376A (enExample) | ||
| EA201791993A1 (ru) | Способы лечения протеинопатий | |
| MY179105A (en) | Methods of treating alzheimer's disease | |
| EA201791199A1 (ru) | Способ лечения болезни альцгеймера | |
| JOP20190191A1 (ar) | وحدات شجرية علاجية | |
| EP4378524A3 (en) | Treatment of fabry disease in ert-naive and ert-experienced patients | |
| MX364785B (es) | Polímeros enlazados al protón para administración oral. | |
| MX377154B (es) | Polimeros de union a protones para administracion oral. | |
| FI3445351T3 (fi) | Asetyylileusiini tai sen farmaseuttisesti hyväksyttävä suola liikkuvuuden parantamiseen | |
| EA201692111A1 (ru) | Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний | |
| EA201691656A2 (ru) | Терапевтические способы с применением норибогаина и родственных соединений | |
| MA39447A1 (fr) | (s)-pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine | |
| MX2019004179A (es) | Composiciones de apilimod y metodos para utilizar las mismas en el tratamiento de la enfermedad de alzheimer. | |
| MA39448A1 (fr) | (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical | |
| BR112018073396A2 (pt) | combinação de antagonistas, uso de uma combinação, método para o tratamento de desordens cognitivas, composto, método para o tratamento de doença de alzheimer e composição farmacêutica | |
| MX2019004200A (es) | Terapia de combinacion. | |
| SG10201809280PA (en) | Combination of brexpiprazole and nalmefene and use thereof for treating substance-related disorders | |
| EA202090416A1 (ru) | Способы лечения симптомов гастропареза с использованием велусетрага | |
| Ito | Investigation of a new treatment outcome index for tuberculosis |